Page last updated: 2024-12-10

2-(4-methoxyphenyl)acetic acid [2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, 2-(4-methoxyphenyl)acetic acid [2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester, is a complex organic molecule with a long and somewhat confusing name. To understand its potential importance for research, let's break down its structure and potential properties:

**Structure:**

* **2-(4-methoxyphenyl)acetic acid:** This is a simple aromatic acid with a methoxy group (-OCH3) attached to the phenyl ring. It's also known as 4-methoxyphenylacetic acid.
* **[2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester:** This is a more complex part of the molecule. It contains an ester linkage (COO) connecting the 2-(4-methoxyphenyl)acetic acid to a long chain with two aniline groups (NH2) and an ethoxy group (-OCH2CH3).

**Potential Properties:**

Given the structure, this compound could exhibit a variety of properties, potentially making it useful for different areas of research:

* **Biological activity:** The presence of multiple aromatic rings, aniline groups, and an ester linkage suggests potential for interaction with biological systems. This molecule might be a candidate for:
* **Drug development:** It could act as a **ligand** binding to specific proteins or enzymes, potentially impacting their function and offering therapeutic applications.
* **Agricultural research:** It could be explored as a **herbicide, pesticide, or fungicide** due to its potential to disrupt key biological processes in unwanted organisms.
* **Materials science:** The presence of aromatic rings and multiple functional groups could lend itself to:
* **Polymers and coatings:** The molecule could be used as a **monomer** for building polymers with unique properties, potentially impacting their strength, flexibility, and conductivity.
* **Organic electronics:** The aromatic structure and potential for electron transfer could make it useful for **organic solar cells, light-emitting diodes (OLEDs), or organic field-effect transistors**.

**Importance in Research:**

The actual importance of this compound in research depends on its specific properties and how they are explored. However, the complexity of its structure and the presence of functional groups that can interact with biological systems and materials suggest its potential as a lead compound for research in various fields.

**To determine its actual importance, further research is required, including:**

* **Synthesis:** The compound needs to be synthesized and purified for characterization.
* **Characterization:** Its physical and chemical properties need to be determined (melting point, solubility, spectroscopy data).
* **Biological testing:** Its interactions with cells, enzymes, and biological systems need to be studied to assess its potential for drug development or agricultural applications.
* **Materials science testing:** Its properties as a monomer, polymer, or material for organic electronics need to be explored.

The process of exploring this compound could lead to valuable discoveries in various fields, highlighting the importance of its initial investigation.

Cross-References

ID SourceID
PubMed CID3650776
CHEMBL ID1454617
CHEBI ID114271

Synonyms (10)

Synonym
HMS2641M11
MLS000335198
smr000249956
CHEBI:114271
[2-[4-[(4-ethoxyphenyl)carbamoyl]anilino]-2-oxoethyl] 2-(4-methoxyphenyl)acetate
CHEMBL1454617
2-(4-methoxyphenyl)acetic acid [2-[4-[(4-ethoxyanilino)-oxomethyl]anilino]-2-oxoethyl] ester
Q27195668
Z18360342
AKOS033611762
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency5.62340.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency4.46680.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency21.13600.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency70.79460.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
DNA polymerase betaHomo sapiens (human)Potency0.31620.022421.010289.1251AID485314
ras-related protein Rab-9AHomo sapiens (human)Potency2.51190.00022.621531.4954AID485297
gemininHomo sapiens (human)Potency1.15820.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]